Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL554261 | 0.98 | CYP2C19 (0.33) | CYP2C19ALDH1A1TSHRMEN1GLA | |
| SCHEMBL5010490 | 0.93 | CA12 (0.39) | CYP2C19ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL32678405 | 0.92 | TSHR (0.39) | CYP2C19ALDH1A1TSHRMEN1GLA | |
| SCHEMBL32678409 | 0.92 | TSHR (0.39) | CYP2C19ALDH1A1TSHRMEN1GLA | |
| SCHEMBL16862666 | 0.92 | ALDH1A1 (0.37) | CYP2C19ALDH1A1TSHRMEN1GLA | |
| SCHEMBL1848044 | 0.90 | CA12 (0.39) | CYP2C19ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL1996756 | 0.90 | CYP2C19 (0.41) | CYP2C19TSHRMEN1GLAKMT2A | |
| SCHEMBL21463022 | 0.84 | CA12 (0.34) | ALDH1A1MEN1KMT2A | |
| SCHEMBL27813321 | 0.84 | — | — | |
| SCHEMBL1998348 | 0.83 | EPHX1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737242-B2 | Crosslinkable siloxane urea copolymers | WACKER CHEMIE AG (DE) | 2010-06-15 | — | — | US | disclosed |
| US-7645516-B2 | Cross-linkable siloxane urea copolymers | WACKER CHEMIE AG (DE) | 2010-01-12 | — | — | US | disclosed |
| EP-1784442-B1 | CROSSLINKABLE SILOXANE UREA COPOLYMERS | WACKER CHEMIE AG (DE) | 2009-10-07 | — | — | EP | disclosed |
| US-20090143496-A1 | CROSSLINKABLE SILOXANE-UREA COPOLYMERS | WACKER CHEMIE AG (DE) | 2009-06-04 | — | — | US | disclosed |
| US-20080045671-A1 | Cross-Linkable Siloxane Urea Copolymers | WACKER CHEMIE AG (DE) | 2008-02-21 | — | — | US | disclosed |
| US-20070232772-A1 | Crosslinkable Siloxane Urea Copolymers | WACKER CHEMIE AG (DE) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143496-A1 | CROSSLINKABLE SILOXANE-UREA COPOLYMERS | CCNT1, PCNA, RAD1 | CYP2C19 3115/4885ALDH1A1 815/4885TSHR 4614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.